Clinical trials: Glaucoma
Primary Open Angle Glaucoma (POAG)
UBM Evaluation After Combined Deep Sclerectomy With Trabeculotomy in Primary Open Angle Glaucoma
Primary open-angle glaucoma is a chronic optic neuropathy that often requires surgical intervention when medical treatment fails.
- Trial name
- NCT07454447
- Testing
- Ultrasound Biomicroscopy
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Minia University Hospital
Primary Open Angle Glaucoma
Comparison Between Latanoprost , Travoprost and Tafluprost in Reducing IOP Fluctuation in POAG Patients
Elevated IOP is a key risk factor for the progression of glaucoma. IOP is subjected to diurnal fluctuation in healthy individuals and higher fluctuation in POAG .
- Trial name
- NCT04461249
- Testing
- Latanoprost 0.005% Ophthalmic Solution, Travoprost 0.004% ophthalmic solution, Tafluprost Ophthalmic 0.0015% Ophthalmic Solution
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Kasr El Aini Hospital
Glaucoma, Narrow Angle
Intraocular Pressure Control After Anterior Segment Laser - Comparison Between 2 Drugs
The purpose of this study is to compare the intra-ocular (IOP) control efficacy between brimonidine 0.1% vs. 0.2% after laser peripheral iridotomy (LPI).
- Trial name
- NCT01417858
- Testing
- YAG laser peripheral iridotomy
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Universidade Federal do Paraná
Open Angle Glaucoma, Ocular Hypertension
MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in subjecs with ocular hypertension or open-angle glaucoma.
- Trial name
- Denali (NCT04630808)
- Testing
- NCX 470 0.1%, Latanoprost 0.005%
- Where
- 88 sites in United States, China
- Volunteers
- 696 people
- Sponsor
- Nicox Ophthalmics, Inc.
Glaucoma
Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow
A 10 week evaluation, crossover design study including a 3 week washout period between treatments, to determine the effects of Combigan® (fixed combination brimonidine tartrate 0.2%/timolol maleate 0.5%) and Cosopt® (fixed…
- Trial name
- NCT00811850
- Testing
- fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution, fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Allergan
Glaucoma
Progression of Disease in Patients Newly Diagnosed With Glaucoma and Glaucoma Suspects Participating in the GATE Study
The purpose of this study is to measure how many patients develop worsening glaucoma in the early years (2-4 years) of routine monitoring in hospital eye services.
- Trial name
- PEG (NCT03394521)
- Testing
- Routine clinical practice
- Volunteers
- 326 people
- Sponsor
- University of Aberdeen
Primary Open Angle Glaucoma, Ocular Hypertension
A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
This is a randomized, Investigator-masked, multi-center, parallel group, therapeutic equivalence study with clinical endpoint.
- Trial name
- NCT05022004
- Testing
- Brinzolamide ophthalmic suspension, Azopt®
- Where
- 40 sites in India, Russia
- Volunteers
- 599 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Primary Open Angle Glaucoma, Ocular Hypertension
Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension
This randomized dose-ranging study will evaluate the safety, tolerability, and preliminary efficacy (reduction in intraocular pressure) of multiple dose levels of ATS907, vehicle, or latanoprost in subjects with primary open…
- Trial name
- NCT01520116
- Testing
- Stage 1 - ATS907 - Dose 1, Stage 1 - ATS907 - Dose 2, Stage 1 - ATS907 - Dose 3
- Where
- 5 sites in United States
- Volunteers
- 180 people
- Sponsor
- Altheos, Inc.
Glaucoma Eye
Assessment of the Occuity PM1 Pachymeter
To determine whether the Occuity PM1 device is non-inferior in measuring central corneal thickness when compared to ultrasound pachymetry, the Lenstar and the Pentacam.
- Trial name
- NCT05895617
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Occuity Limited
Glaucoma, OCTA
Choroidal and Retinal Features in PACD and POAG on OCT and OCTA
Glaucoma is a group of irreversible, progressive optic neuropathies that can lead to severe visual field defects and even blindness, affecting nearly 95 million people worldwide.
- Conditions
- Glaucoma, OCTA, Choroid
- Trial name
- NCT07580014
- Where
- China
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Open-angle Glaucoma
Two Trabecular Micro-bypass Stents & Postoperative Travoprost to Treat Glaucoma Subjects on Two Hypotensive Agents
The study objective was to evaluate the intraocular pressure (IOP) lowering effect of two iStent devices in eyes of subjects with primary open-angle glaucoma, washed out of two anti-glaucoma medications (one a Prostaglandin)…
- Trial name
- NCT02873806
- Testing
- Implantation of two iStent inject micro-bypass stents, Topical travoprost, Two iStent inject micro-bypass stents
- Where
- Armenia
- Volunteers
- 53 people
- Sponsor
- Glaukos Corporation
Glaucoma, Ocular Hypertension
Efficacy of the Nanodropper Device on Intraocular Pressure in Patients With Glaucoma
Glaucoma is the leading cause of irreversible blindness worldwide. Previous studies demonstrate that smaller eye drops used in the treatment of glaucoma are just as efficacious as their larger counterparts.
- Conditions
- Glaucoma, Ocular Hypertension, Open Angle Glaucoma
- Trial name
- NCT05273385
- Testing
- Nanodropper
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, San Francisco
Optic Neuropathy
STReetlab Assessment Tool of Activities Daily Living in Glaucoma Patient
The impact of glaucomatous optic neuropathy on the daily life of patients is poorly characterized and does not benefit from standardized tests.
- Trial name
- STRATAL-GL (NCT05747781)
- Testing
- Pilot Phase: standardized behavioral task, Validation Phase: standardized behavioral task
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Glaucoma, Primary Open Angle
Adaptive Optics Retinal Imaging
The objective of the study is to collect and assess adaptive optics (AO) retinal images from human subjects in support of projects to demonstrate, advance, and enhance clinical use of AO technology.
- Trial name
- NCT05370287
- Testing
- oxygen inhalation, Adaptive optics imaging
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Food and Drug Administration (FDA)
Glaucoma
Effects of Palmitoylethanolamide on Inner Retinal Function in Glaucoma Patients by Pattern Electroretinogram
The general purpose of the study is to evaluate the potential beneficial effects of PEA 600 mg supplementation on RGCs function in subjects with glaucoma by pattern electroretinogram after three months of therapy.
- Trial name
- NCT04088084
- Testing
- palmitoylethanolamide (PEA) 600 mg
- Volunteers
- 40 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Cognitive Behavioral Nursing, Congenital Glaucoma
Cognitive Behavioral Nursing Model
Materials and Methods 1. General information This study enrolled 153 patients with congenital glaucoma who were treated at our hospital from January 2021 to December 2022.
- Trial name
- NCT05943184
- Testing
- Cognitive Behavioral Nursing Model
- Where
- China
- Volunteers
- 153 people
- Sponsor
- Taiyuan Central Hospital of Shanxi Medical University
Glaucoma, Ocular Hypertension
A Study of the Safety and Efficacy of Bimatoprost in Patients With Glaucoma or Ocular Hypertension
A one month study which will determine the safety and efficacy of bimatoprost eye drops in patients with glaucoma or ocular hypertension
- Trial name
- NCT00538304
- Testing
- bimatoprost eye drops
- Where
- United States
- Volunteers
- 222 people
- Sponsor
- Allergan
Primary Open-angle Glaucoma
GORE Glaucoma Drainage Implant Clinical Study Dominican Republic
The objective of this early feasibility clinical study is to evaluate the safety and effectiveness of several different GORE Glaucoma Drainage Implant configurations in subjects with primary open-angle glaucoma that is…
- Trial name
- NCT05557058
- Testing
- Gore Glaucoma Device Implant (GORE GDI)
- Where
- Dominican Republic
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- W.L.Gore & Associates
Primary Open Angle Glaucoma, Primary Angle Closure Glaucoma
Patch Graft Material Safety and Effectiveness in Covering Glaucoma Drainage Device Tube
The investigators hypothesize that KeraSys is a safe as Tutoplast to cover the tube of the Molteno 3 glaucoma drainage device during surgery
- Conditions
- Primary Open Angle Glaucoma, Primary Angle Closure Glaucoma, Pseudoexfoliation Glaucoma, Pigmentary Glaucoma
- Trial name
- NCT01301378
- Testing
- Molteno 3 glaucoma drainage shunt
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Wills Eye
Glaucoma
Effect of Citicoline/Homotaurine on PERG in Primary Open Angle Glaucoma
the general purpose of the study is to evaluate the potential beneficial effects of supplementation of a fixed combination of Citicoline 500 mg plus Homotaurine 50 mg on retinal ganglion cells (RGCs) function in subjects with…
- Trial name
- NCT04422743
- Testing
- Citicoline 500 mg plus Homotaurine 50 mg
- Where
- 4 sites in Italy
- Volunteers
- 63 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia